User login
Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).
Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.
Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.
Disclosures: This work was supported by National Cancer Institute.
Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.
Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).
Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.
Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.
Disclosures: This work was supported by National Cancer Institute.
Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.
Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).
Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.
Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.
Disclosures: This work was supported by National Cancer Institute.
Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.